By Jason Chau – Wall Street Journal –
Japanese pharmaceutical major Takeda is forging an AI drug-discovery partnership with biotech firm Insilico Medicine with a potential initial value of $600.0 million.
Under the partnership announced Thursday, Takeda will pay Insilico to use its proprietary Pharma.AI platform to advance drug candidates across several therapeutic areas. Insilico will lead drug discovery, while Takeda will further development, including advancing candidates past clinical trials.
